Effect of Trifolium pratense-derived isoflavones on the lipid profile of postmenopausal women with increased body mass index

References

• Bhavnani B R, Strickler R C. Menopausal hormone therapy. J Obstet Gynaecol Can 2005; 27: 137–162
   PubMedGoogle Scholar
• Castelo-Branco C, Rostro F. Management of menopause. Minerva Ginecol 2006; 58: 137–152
   PubMedGoogle Scholar
• Rossouw J E, Anderson G L, Prentice R L, LaCroix A Z, Kooperberg C, Stefanick M L, Jackson R D, Beresford S A, Howard B V, Johnson K C, Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Blumel J E, Castelo-Branco C, Chedraui P A, Binfa L, Dowlani B, Gomez M S, Sarra S. Patients' and clinicians' attitudes after the Women's Health Initiative study. Menopause 2004; 11: 57–61
   PubMed Web of Science ®Google Scholar
• Ettinger B, Grady D, Tosteson A N, Pressman A, Macer J L. Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003; 102: 1225–1232
   PubMed Web of Science ®Google Scholar
• Lazar F Jr, Costa-Paiva L, Morais S S, Pedro A O, Pinto-Neto A M. The attitude of gynecologists in Sao Paulo, Brazil 3 years after the Women's Health Initiative study. Maturitas 2007; 56: 129–141
   Google Scholar
• Nassar A H, Abd Essamad H M, Awwad J T, Khoury N G, Usta I M. Gynecologists' attitudes towards hormone therapy in the post ‘Women's Health Initiative’ study era. Maturitas 2005; 52: 18–25
   PubMed Web of Science ®Google Scholar
• Miksicek R J. Commonly occurring plant flavonoids have estrogenic activity. Mol Pharmacol 1993; 44: 37–43
   PubMed Web of Science ®Google Scholar
• Miksicek R J. Interaction of naturally occurring nonsteroidal estrogens with expressed recombinant human estrogen receptor. J Steroid Biochem Mol Biol 1994; 49: 153–160
   PubMed Web of Science ®Google Scholar
• Dornstauder E, Jisa E, Unterrieder I, Krenn L, Kubelka W, Jungbauer A. Estrogenic activity of two standardized red clover extracts (Menoflavon) intended for large scale use in hormone replacement therapy. J Steroid Biochem Mol Biol 2001; 78: 67–75
   PubMed Web of Science ®Google Scholar
• Simoncini T, Fornari L, Mannella P, Caruso A, Garibaldi S, Baldacci C, Genazzani A R. Activation of nitric oxide synthesis in human endothelial cells by red clover extracts. Menopause 2005; 12: 69–77
   PubMed Web of Science ®Google Scholar
• Rathel T R, Leikert J F, Vollmar A M, Dirsch V M. The soy isoflavone genistein induces a late but sustained activation of the endothelial nitric oxide-synthase system in vitro. Br J Pharmacol 2005; 144: 394–399
   PubMedGoogle Scholar
• Imhof M, Gocan A, Reithmayr F, Lipovac M, Schimitzek C, Chedraui P, Huber J. Effects of a red clover extract (MF11RCE) on endometrium and sex hormones in postmenopausal women. Maturitas 2006; 55: 76–81
   PubMed Web of Science ®Google Scholar
• Chedraui P, Hidalgo L, San Miguel G, Morocho N, Ross S. Red clover extract (MF11RCE) supplementation and postmenopausal vaginal and sexual health. Int J Gynaecol Obstet 2006; 95: 296–297
   PubMed Web of Science ®Google Scholar
• Hidalgo L A, Chedraui P A, Morocho N, Ross S, San Miguel G. The effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women: a randomized, double-blind, placebo-controlled study. Gynecol Endocrinol 2005; 21: 257–264
   PubMed Web of Science ®Google Scholar
• Samman S, Lyons Wall P M, Chan G S, Smith S J, Petocz P. The effect of supplementation with isoflavones on plasma lipids and oxidisability of low density lipoprotein in premenopausal women. Atherosclerosis 1999; 147: 277–283
   PubMed Web of Science ®Google Scholar
• Atkinson C, Oosthuizen W, Scollen S, Loktionov A, Day N E, Bingham S A. Modest protective effects of isoflavones from a red clover-derived dietary supplement on cardiovascular disease risk factors in perimenopausal women, and evidence of an interaction with ApoE genotype in 49–65 year-old women. J Nutr 2004; 134: 1759–1764
   PubMed Web of Science ®Google Scholar
• Nestel P, Cehun M, Chronopoulos A, DaSilva L, Teede H, McGrath B. A biochanin-enriched isoflavone from red clover lowers LDL cholesterol in men. Eur J Clin Nutr 2004; 58: 403–408
   PubMed Web of Science ®Google Scholar
• Howes J B, Sullivan D, Lai N, Nestel P, Pomeroy S, West L, Eden J A, Howes R G. The effects of dietary supplementation with isoflavones from red clover on the lipoprotein profiles of post menopausal women with mild to moderate hypercholesterolaemia. Atherosclerosis 2000; 152: 143–147
   PubMed Web of Science ®Google Scholar
• Blakesmith S J, Lyons-Wall P M, George C, Joannou G E, Petocz P, Samman S. Effects of supplementation with purified red clover (Trifolium pratense) isoflavones on plasma lipids and insulin resistance in healthy premenopausal women. Br J Nutr 2003; 89: 467–474
   PubMed Web of Science ®Google Scholar
• Hidalgo L A, Chedraui P A, Morocho N, Alvarado M, Chavez D, Huc A. The metabolic syndrome among postmenopausal women in Ecuador. Gynecol Endocrinol 2006; 22: 447–454
   PubMed Web of Science ®Google Scholar
• Royer M, Castelo-Branco C, Blumel J E, Chedraui P A, Danckers L, Bencosme A, Navarro D, Vallejo S, Espinoza M T, Gómez G, , Collaborative Group for Research of the Climacteric in Latin America, et al. The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III): prevalence of the metabolic syndrome in postmenopausal Latin American women. Climacteric 2007; 10: 164–170
   PubMed Web of Science ®Google Scholar
• Alexander J, Clearfield M. Cardiovascular disease after menopause: a growing epidemic. Minerva Ginecol 2006; 58: 35–40
   PubMedGoogle Scholar
• Chedraui P, Hidalgo L, Chavez D, Morocho N, Alvarado M, Huc A. Quality of life among postmenopausal Ecuadorian women participating in a metabolic syndrome screening program. Maturitas 2007; 56: 45–53
   PubMed Web of Science ®Google Scholar
• Chedraui P, Hidalgo L, Chavez D, Morocho N, Alvarado M, Huc A. Menopausal symptoms and associated risk factors among postmenopausal women screened for the metabolic syndrome. Arch Gynecol Obstet 2007; 275: 161–168
   PubMedGoogle Scholar
• Wang M F, Yamamoto S, Chung H M, Chung S Y, Miyatani S, Mori M, Okita T, Sugano M. Antihypercholesterolemic effect of undigested fraction of soybean protein in young female volunteers. J Nutr Sci Vitaminol (Tokyo) 1995; 41: 187–195
   PubMedGoogle Scholar
• Schult T M, Ensrud K E, Blackwell T, Ettinger B, Wallace R, Tice J A. Effect of isoflavones on lipids and bone turnover markers in menopausal women. Maturitas 2004; 48: 209–218
   PubMed Web of Science ®Google Scholar
• Clifton-Bligh P B, Baber R J, Fulcher G R, Nery M L, Moreton T. The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism. Menopause 2001; 8: 259–265
   PubMed Web of Science ®Google Scholar
• Cancellieri F, De Leo V, Genazzani A D, Nappi C, Parenti G L, Polatti F, Ragni N, Savoca S, Teglio L, Finelli F, et al. Efficacy on menopausal neurovegetative symptoms and some plasma lipids blood levels of an herbal product containing isoflavones and other plant extracts. Maturitas 2007; 56: 249–256
   PubMed Web of Science ®Google Scholar
• Allen J K, Becker D M, Kwiterovich P O, Lindenstruth K A, Curtis C. Effect of soy protein-containing isoflavones on lipoproteins in postmenopausal women. Menopause 2007; 14: 106–114
   Google Scholar
• Nahas E A, Nahas-Neto J, Orsatti F L, Carvalho E P, Oliveira M L, Dias R. Efficacy and safety of a soy isoflavone extract in postmenopausal women: a randomized, double-blind, and placebo-controlled study. Maturitas 2007; 58: 249–258
   PubMed Web of Science ®Google Scholar
• Aubertin-Leheudre M, Lord C, Khalil A, Dionne I J. Effect of 6 months of exercise and isoflavone supplementation on clinical cardiovascular risk factors in obese postmenopausal women: a randomized, double-blind study. Menopause 2007; 14: 624–629
   PubMed Web of Science ®Google Scholar
• Bennet A, Di Angelantonio E, Erqou S, Eiriksdottir G, Sigurdsson G, Woodward M, Rumley A, Lowe G D, Danesh J, Gudnason V. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med 2008; 168: 598–608
   PubMed Web of Science ®Google Scholar
• Shai I, Schulze M B, Manson J E, Stampfer M J, Rifai N, Hu F B. A prospective study of lipoprotein(a) and risk of coronary heart disease among women with type 2 diabetes. Diabetologia 2005; 48: 1469–1476
   Google Scholar